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EZH2 may function to methylate nonhistone proteins,
methylate histone proteins, or act as a transcription factor,
which up-regulates or down-regulates gene expression on
the basis of context within the cell.1 As a master regulator,
EZH2 can have long-standing effects on development that
lead to increased risk of disease later in life. For example,
early work showed that treatment of mice with xenoes-
trogens, such as diethylstilbestrol, led to inactivation of
EZH2, subsequent reprogramming of estrogen-responsive
genes, and increased sensitivity to the proliferative effects
of estradiol in the uterus.2,3 However, the role of EZH2 in
uterine development has not been described. In this issue of
The American Journal of Pathology, Fang et al4 report on
the impact of conditional deletion of Ezh2 in the mouse
uterus, using a progesterone-driven Cre recombinase
[Ezh2 conditional knockout (cKO)].
Uterine Epithelial Development
Mouse and human endometrium is composed of luminal
epithelium that invaginates to form glandular epithelium,
which is surrounded by endometrial stromal cells.5,6 Several
genes, including catenin b 1 (Ctnnb1), forkhead box A2
(Foxa2), leucine-rich repeat-containing G-proteinecoupled
receptor 4 (Lgr4), wingless-related mouse mammary tumor
virus (MMTV) integration site 4 (Wnt4), and Wnt7a, regu-
late uterine epithelium development and differentiation.7
Fang et al4 add Ezh2 to the list of genes important in uter-
ine epithelial cell development.
The key function of the endometrium is in the implantation
process of the blastocyst. Each component of the endometriumCopyright ª 2019 American Society for Investigative Pathology. Published by Elsevier Inc
https://doi.org/10.1016/j.ajpath.2019.03.007plays a unique molecular role in embryo implantation. Both
luminal epithelium and glandular epithelium are histologically
columnar epithelial cells. However, they differ in shape, loca-
tion, and molecular function, particularly regarding steroid
hormone and nonesteroid hormone signaling cascades.5,8
Luminal epithelium is critical for uterine receptivity, embryo
attachment, and furthering differentiation-signaling cascades.
Glandular epithelium is important for angiogenesis and suc-
cessful implantation and continuation of pregnancy.5,8 The
Ezh2 cKO mouse uterine epithelium exhibits a unique
morphologic change. Specifically, the normal single layer of
columnar glandular epithelium is replaced by stratified
columnar epithelium.Consistentwith endometrial hyperplasia,
the endometrium contains an increased number of dilated
glands separated by normal stroma. More important, deletion
of Ezh2 in the uterus results in fertility defects.4Molecular Impact
In Ezh2 cKO mice, uterine epithelium development was
dysregulated at the molecular level. In particular, there was an
aberrant expression of basalis cell markers.4 The endome-
trium is composed of the stratum compactum, stratum spon-
giosum, and stratum basalis. Both the stratum compactum. All rights reserved.
EZH2 in Uterine Developmentand stratum spongiosum make up the stratum functionalis,
which exhibits large changes through the menstrual cycle.9 In
contrast, the stratum basalis remains more histologically
constant and is changed with replacing tissue lost during
menstruation, potentially through stem-like or progenitor
cells in the basalis.10e12 Transformation-related protein 63
(p63), alias tumor protein p63, is involved in the development
of the epithelial basal layer.13 The p63 gene contains two
main isoforms by alternative promoters that contain a p53-
like N-terminal transactivation domain and lack this
domain.14 The uterine epithelium of Ezh2 cKO mice con-
tained high levels of p63 that lacked the N-terminal trans-
activation domain, consistent with an increased basal cell
phenotype.4 Recent work has shown that neonatal exposure
to estrogenic chemicals, such as diethylstilbestrol, affects p63
expression by increasing the number and location of basal
cells and increasing the risk of uterine carcinoma in adults.15
The p63may be amarker of metaplastic differentiation and/or
initiation of epithelial stratification.16 EZH2 may play a
similar role and/or regulate p63 expression.
The Future of EZH2 Inhibitors
EZH2 inhibitors hold significant promise as new therapies
for switch/sucrose nonefermentable (SWI/SNF)-mutated
cancers.17 The SWI/SNF complex, involved in chromatin
remodeling, is composed of approximately 15 subunits, such
as ARID1A and SMARCA4. Next-generation sequencing
studies across multiple different cancer types have shown
that members of the SWI/SNF complex are frequently
mutated in cancer, with a range of mutation frequency from
9% in triple-negative breast cancer to 75% in ovarian clear
cell carcinoma.18 Important translational studies have shown
that EZH2 inhibitors demonstrate increased efficacy in
ARID1A-mutated cancers.17 The function of EZH2 in the
endometrium is critical to understanding normal develop-
ment, but also, it is critical to understanding the pharmaco-
logic effects of EZH2 inhibitors on tissues other than cancer.
Deletion of Ezh2 in the mouse uterus results in simple hy-
perplasia that is histologically similar to the endometrial
histology of women treated with ulipristal, a selective pro-
gesterone receptor modulator.19 On the basis of data from
this Ezh2 cKO mouse model,4 as clinical trials progress for
EZH2 inhibitors, careful consideration for fertility and
endometrial evaluation are critical.
References
1. Kim KH, Roberts CW: Targeting EZH2 in cancer. Nat Med 2016, 22:
128e134The American Journal of Pathology - ajp.amjpathol.org2. Walker CL: Epigenomic reprogramming of the developing reproduc-
tive tract and disease susceptibility in adulthood. Birth Defects Res A
Clin Mol Teratol 2011, 91:666e671
3. Bredfeldt TG, Greathouse KL, Safe SH, Hung MC, Bedford MT,
Walker CL: Xenoestrogen-induced regulation of EZH2 and histone
methylation via estrogen receptor signaling to PI3K/AKT. Mol
Endocrinol 2010, 24:993e1006
4. Fang X, Ni N, Lydon JP, Ivanov I, Bayless KJ, Rijnkels M, Li Q:
EZH2 is required for uterine epithelial integrity. Am J Pathol
2019, 189:1212e1225
5. Cha J, Sun X, Dey SK: Mechanisms of implantation: strategies for
successful pregnancy. Nat Med 2012, 18:1754e1767
6. Filant J, Spencer TE: Uterine glands: biological roles in conceptus
implantation, uterine receptivity and decidualization. Int J Dev Biol
2014, 58:107e116
7. Spencer TE: Biological roles of uterine glands in pregnancy. Semin
Reprod Med 2014, 32:346e357
8. Evans GE, Martinez-Conejero JA, Phillipson GT, Sykes PH, Sin IL,
Lam EY, Print CG, Horcajadas JA, Evans JJ: In the secretory endo-
metria of women, luminal epithelia exhibit gene and protein expres-
sions that differ from those of glandular epithelia. Fertil Steril 2014,
102:307e317.e7
9. Huang EC, Crum CP, Hornstein MD: Chapter 16 - Evaluation of the
cyclic endometrium and benign endometrial disorders. Diagnostic and
Gynecologic and Obstetric Pathology. Philadelphia, PA: Elsevier,
2017. pp. 471e523
10. Prianishnikov VA: On the concept of stem cell and a model of
functional-morphological structure of the endometrium. Contraception
1978, 18:213e223
11. Gargett CE, Chan RW, Schwab KE: Hormone and growth factor
signaling in endometrial renewal: role of stem/progenitor cells. Mol
Cell Endocrinol 2008, 288:22e29
12. Schwab KE, Hutchinson P, Gargett CE: Identification of surface
markers for prospective isolation of human endometrial stromal
colony-forming cells. Hum Reprod 2008, 23:934e943
13. O’Connell JT, Mutter GL, Cviko A, Nucci M, Quade BJ,
Kozakewich HP, Neffen E, Sun D, Yang A, McKeon FD, Crum CP:
Identification of a basal/reserve cell immunophenotype in benign and
neoplastic endometrium: a study with the p53 homologue p63.
Gynecol Oncol 2001, 80:30e36
14. Murray-Zmijewski F, Lane DP, Bourdon JC: p53/p63/p73 Isoforms:
an orchestra of isoforms to harmonise cell differentiation and response
to stress. Cell Death Differ 2006, 13:962e972
15. Suen AA, Jefferson WN, Williams CJ, Wood CE: Differentiation
patterns of uterine carcinomas and precursor lesions induced by
neonatal estrogen exposure in mice. Toxicol Pathol 2018, 46:574e596
16. Koster MI, Kim S, Mills AA, DeMayo FJ, Roop DR: p63 Is the
molecular switch for initiation of an epithelial stratification program.
Genes Dev 2004, 18:126e131
17. Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M,
Kossenkov AV, Schultz DC, Liu Q, Shih I-M, Conejo-Garcia JR,
Speicher DW, Zhang R: Synthetic lethality by targeting EZH2 meth-
yltransferase activity in ARID1A-mutated cancers. Nat Med 2015, 21:
231e238
18. Shain AH, Pollack JR: The spectrum of SWI/SNF mutations, ubiqui-
tous in human cancers. PLoS One 2013, 8:e55119
19. Bressler LH, Bernardi LA, Snyder MA, Wei JJ, Bulun S: Treatment of
endometriosis-related chronic pelvic pain with ulipristal acetate and
associated endometrial changes. HSOA J Reprod Med Gynaecol
Obstet 2017, 2. 0081177
